Sacral neuromodulation for lower urinary tract dysfunction: 14-year experience at single center
Chen Guoqing1, 2 Liao Limin1, 2
1Department of Urology, China Rehabilitation Research Center, Beijing Bo'ai Hospital, Beijing 100068, China; 2Department of Urology, Capital Medical University
Abstract：Objective: To summarize 14-year experience with sacral neuromodulation (SNM) for lower urinary tract dysfunction at our center. Methods: We retrospectively reviewed the patient database at our center to assess the long-term outcome and incidence of adverse events after sacral neuromodulation implantation for lower urinary tract dysfunction between 2002 and 2016. Results: Between May 2002 and Apr. 2016, 69 patients were given a preliminary test SNM. In the test phase, the rate of improvement was 100% (7/7) in overactivity bladder, 66.7% (6/9) in non-obstructive urinary retention and 50.0% (4/8) in interstitial cystitis. In neurogenic bladder patients, the rate of improvement in dysuria (23.1%, 9/39) was significantly lower than in urgency-frequency (54.2%, 13/24), urinary incontinence (64.2%, 12/19), constipation (63.9%, 23/36) and bladder pain (50%, 2/4). At last, an implant was performed on 35 (50.7%) patients. The conversion rate from testing phase to implantation phase was 58.3% (14/24) in non-neurogenic bladder patients and 46.7% (21/45) in neurogenic bladder patients. During the follow-up period (35.8±7.7 months), the long-term success rate was 88.6%. Conclusions: SNM is a minimally invasive procedure with a good long-term outcome to treat lower urinary tract dysfunction.
[1]陈国庆,宋勇,丁留成,等.骶神经调节术临床应用中国专家共识.中华泌尿外科杂志,2014,35(1):1-5. [2]Schmidt RA, Bruschini H, Tanagho EA. Sacral root stimulation in controlled micturition. Peripheral somatic neurotomy and stimulated voiding. Invest Urol, 1979,17(2):130-134. [3]Steele SS. Sacral nerve stimulation: 50 years in the making. Can Urol Assoc J, 2012,6(4):231-232. [4]Chen G, Liao L. Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease. Spinal Cord, 2015:204-208. [5]陈国庆,廖利民,史文博,等.骶神经调节治疗神经源性膀胱患者大小便功能障碍的疗效评估.中华泌尿外科杂志,2015,36(2):87-90. [6]张耀光,王建业,张大磊,等.骶神经调节治疗膀胱盆底疼痛综合征/间质性膀胱炎患者的初步临床结果.中华泌尿外科杂志,2015,36(2):91-94. [7]Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum, 1996,39(6):681-685. [8]Leong RK, De Wachter SG, Nieman FH, et al. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method toidentify patients suitable for sacral neuromodulation therapy. Neurourol Urodyn, 2011,30(7):1249-1252. [9]Kessler TM, La Framboise D, Trelle S, et al. Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: Systematic Review and Meta-analysis. Eur Urol, 2010,58(6):865-874. [10]Drossaerts J, Vrijens D, Leue C, et al. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation. Neurourol Urodyn. 2015,Sep 9. http://onlinelibrary.wiley.com/doi/10.1002/nau.22871/abstract;jsessionid=A4693E735FCC9467F37300D689A9658B.f04t03. [11]Peters KM, Killinger KA, Gilleran JP, et al. Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients. Neurourol Urodyn, 2015, Nov 20. http://onlinelibrary.wiley.com/doi/10.1002/nau.22929/abstract [12]Butrick CW. Patient selection for sacral nerve stimulation. Int Urogynecol J, 2010, Suppl 2:S447-451. [13]Marcelissen TA, Leong RK, Nieman FH, et al. The effect of pulse rate changes on the clinical outcome of sacral neuromodulation. J Urol, 2011,185(5):1781-1785.
